news aktuell GmbH

JP Hospitality acquires tradition-rich vintage hotel in heart of Madonna di Campiglio’s town centre

Share

Fourth acquisition by Viennese investor group in 2022

Vienna, 28th of June 2022

The JP Hospitality Investors Club has acquired Hotel Milano in Madonna di Campiglio (altitude: 1,600 metres), a property surrounded by the breathtaking mountain scenery of the Brenta Dolomites.

Daniel Jelitzka, founder of JP Immobilien Group and chairman of the Advisory Board at JP Hospitality, explained that the acquisition of Hotel Milano fits into the Investors Club’s strategy very well: “Madonna di Campiglio is a one-of-a-kind ski town in the northern Italian Alps with its own unique charm, and it offers the ideal conditions for a wide range of winter and summer tourist activities. With a refurbished, hip hotel and an attractive range of culinary offerings, we will cover the resilient and very much in demand lifestyle segment here.”

The hotel offers around 50 rooms and is located in the middle of the pedestrian zone in the Alpine village of Madonna di Campiglio, roughly a one-minute walk from the valley chairlift station for the famous World Cup race course. In collaboration with an international operator, the hotel will be renovated and repositioned as a mid to upscale Alpine lifestyle hotel.

“We will give an existing property a modern update with a clear design and develop it into an Alpine lifestyle hotel located in one of Europe’s most attractive Alpine winter and summer tourist destinations,” commented Lukas Euler-Rolle, CEO of JP Hospitality, enthusiastically.

Gebhard Schachermayer, CAM of JP Hospitality, pointed out that “the vintage hotel features an ideal location in the heart of the town centre and has tremendous catch-up potential with modern F&B and wellness offerings.”

Download

Keywords

Contacts

Petra Menasse-Eibensteiner / JP Immobilien
+43 699 126 39 220
petra@menassemenasse.at

Links

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain ​18.8.2022 13:11:21 CEST | Press release

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi

An ordeal that ends on a plate in a tourist resort: Live transports of calves to the Canary Islands9.8.2022 16:47:11 CEST | Press release

Every week, cattle are shipped to the Canary Islands under unacceptable conditions. These transports are extremely long. The animals stand on the truck for even more than 100 hours non-stop. Now, in summer, sweltering heat must be added as well as poor water supply, no or too little food, bedding of excrements and urine, lack of space, and an acrid ammonia smell. Once on the islands, the animals, only a few months old, await death in the slaughterhouse. A trade that is enhanced by subsidies and slaughter premiums .

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million4.8.2022 09:00:00 CEST | Press release

Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee. RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints. Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Thereof, Shionogi will pay $ 75 mil

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom